--- title: "Cagrilintide | PepTracker Pro" description: "A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Cagrilintide", "description": "A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.", "url": "https://peptrackerpro.com/peptides/cagrilintide", "lastReviewed": "2026-06-13", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Cagrilintide", "item": "https://peptrackerpro.com/peptides/cagrilintide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching amylin-based therapies?", "acceptedAnswer": { "@type": "Answer", "text": "Cagrilintide is a research peptide studied in preclinical models. A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026." } }, { "@type": "Question", "name": "Those following CagriSema clinical trials?", "acceptedAnswer": { "@type": "Answer", "text": "Cagrilintide is a research peptide studied in preclinical models. A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026." } }, { "@type": "Question", "name": "Individuals comparing appetite-regulation compounds?", "acceptedAnswer": { "@type": "Answer", "text": "Cagrilintide is a research peptide studied in preclinical models. A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026." } } ] } ] --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Cagrilintide **Research-only content.** This page is for educational purposes and does not constitute medical advice. [Read full disclaimer →](/research-disclaimer) # Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Aliases NN9838 +1 more Evidence High Evidence Last Updated 2026-06-13 Reading Time 3 min ## Table of Contents 1. [What It Is](#what-it-is) 2. [Proposed Mechanisms](#proposed-mechanisms) 3. [Evidence Snapshot](#evidence-snapshot) 4. [Commonly Discussed Benefits](#benefits) 5. [Safety & Cautions](#safety) 6. [Comparisons](#comparisons) 7. [Calculator Tools](#calculator) 8. [Citations](#citations) ## What It Is Cagrilintide is a long-acting analog of the hormone amylin, which is naturally co-secreted with insulin from pancreatic beta cells. It works by slowing gastric emptying, promoting satiety, and reducing glucagon secretion. It is the amylin component of CagriSema, a once-weekly fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. On December 18, 2025, Novo Nordisk submitted a New Drug Application (NDA) to the FDA for CagriSema for chronic weight management — making it the first GLP-1/amylin combination to reach NDA stage. Both pivotal Phase 3 trials were published in the New England Journal of Medicine in 2026. In REDEFINE-1, CagriSema achieved 20.4% mean weight loss at 68 weeks, with 60% of participants losing ≥20% and 23% losing ≥30% body weight. In REDEFINE-2 (adults with obesity and T2D), CagriSema achieved 13.7% mean weight loss and 73.5% of participants reached HbA1c ≤6.5% vs 15.9% with placebo. Gastrointestinal AEs affected 79.6% of the CagriSema group but were mostly transient and mild-to-moderate. CagriSema initially fell short of an internal 25% weight loss target, which briefly pressured Novo Nordisk's stock price, though the 22.7% on-treatment weight loss still exceeds most competitors. The FDA is expected to render a decision by approximately October 2026 under standard review timelines. In April 2026, Novo Nordisk announced positive headline results from REIMAGINE-2, a Phase 3 trial in adults with overweight or obesity and type 2 diabetes. CagriSema 2.4 mg/2.4 mg demonstrated superior HbA1c reduction of 1.91 percentage points versus 1.76 with semaglutide 2.4 mg alone (from a baseline of 8.2%), and superior weight loss of 14.2% versus 10.2% with semaglutide alone (from a baseline of ~101 kg) at 68 weeks. These results confirm CagriSema's incremental benefit over its GLP-1 component alone in the T2D population. Also known as: NN9838, CagriSema component ## Proposed Mechanisms - Activates amylin receptors in the area postrema to reduce appetite and caloric intake - Slows gastric emptying, prolonging post-meal satiety signals - Reduces post-prandial glucagon secretion, improving glycemic control - Complements GLP-1 agonism through an independent anorexigenic pathway - Long-acting albumin-binding design extends half-life to once-weekly dosing ## Evidence Snapshot High Evidence Low Medium High Study Type Model Outcome Link Human (Phase 3) REDEFINE-1: Adults with obesity, no T2D (n=3,417) 20.4% mean weight loss at 68 weeks vs 3.0% placebo [Source](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) Human (Phase 3) REDEFINE-2: Adults with obesity + T2D (n=1,507) 13.7% mean weight loss at 68 weeks vs 3.4% placebo [Source](https://www.nejm.org/doi/full/10.1056/NEJMoa2502082) Human (Phase 2) Healthy adults with overweight/obesity Dose-dependent weight loss, well-tolerated GI side effects [Source](https://pubmed.ncbi.nlm.nih.gov/) ## Commonly Discussed Benefits [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism) Researching Cagrilintide ? Track it, set reminders, and keep notes in the free app. [Track in App](https://app.peptrackerpro.com/?add=cagrilintide) ## Safety & Cautions - NDA filed December 2025; FDA decision expected ~October 2026 - Gastrointestinal side effects observed in 79.6% of CagriSema group (mostly mild-to-moderate and transient) - Missed internal 25% weight loss target in REDEFINE-1 — achieved 22.7% on-treatment - Primarily studied in combination with semaglutide, not as standalone - Not yet FDA-approved - Context (June 2026): interest in lean-mass-sparing weight loss is widening beyond amylin agonists. A small early-stage trial of the endocannabinoid-system peptide Pep19 reported visceral-fat reduction without lean-mass loss — a different mechanism worth distinguishing from amylin-based approaches like cagrilintide. ## Comparisons See how Cagrilintide compares to related peptides: [Cagrilintide vs ALV-200](/compare/cagrilintide-vs-alv-200) [Cagrilintide vs ASC39](/compare/cagrilintide-vs-asc39) [Cagrilintide vs CagriSema](/compare/cagrilintide-vs-cagrisema) [Cagrilintide vs Maridebart Cafraglutide (MariTide)](/compare/cagrilintide-vs-maridebart-cafraglutide) [Cagrilintide vs MET-233i](/compare/cagrilintide-vs-met-233i) [Cagrilintide vs Pep19](/compare/cagrilintide-vs-pep19) [Cagrilintide vs Semaglutide](/compare/cagrilintide-vs-semaglutide) [Cagrilintide vs Survodutide](/compare/cagrilintide-vs-survodutide) [Cagrilintide vs Tirzepatide](/compare/cagrilintide-vs-tirzepatide) ## Calculator Tools Use our research tools to explore dosing and reconstitution data: [Reconstitution Calculator](/calculators) ## Citations 1. \[1\] Novo Nordisk — CagriSema NDA filing announcement. December 2025 [PubMed](https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-302645862.html) 2. \[2\] REDEFINE-1 — Cagrilintide-Semaglutide in Adults with Overweight or Obesity, NEJM 2026 [PubMed](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) 3. \[3\] REDEFINE-2 — Cagrilintide-Semaglutide in Adults with T2D, NEJM 2026 [PubMed](https://www.nejm.org/doi/full/10.1056/NEJMoa2502082) 4. \[4\] Novo Nordisk submits NDA for CagriSema — PharmExec, April 2026 [PubMed](https://www.pharmexec.com/view/novo-nordisk-submits-nda-fda-cagrisema) 5. \[5\] Novo Nordisk — REIMAGINE-2 Phase 3 headline results, April 2026 [PubMed](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481) ### Keep researching in the app - Log Cagrilintide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack [Open PepTracker Pro Free](https://app.peptrackerpro.com/?add=cagrilintide) [Browse more peptides](/peptides) ## Related Peptides ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/alv-200) [\+ Compare](/compare?select=alv-200)[](https://app.peptrackerpro.com/?add=alv-200) ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/asc39) [\+ Compare](/compare?select=asc39)[](https://app.peptrackerpro.com/?add=asc39) ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism) [View Details](/peptides/cagrisema) [\+ Compare](/compare?select=cagrisema)[](https://app.peptrackerpro.com/?add=cagrisema) ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Appetite Regulation](/benefits/appetite-regulation)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/maridebart-cafraglutide) [\+ Compare](/compare?select=maridebart-cafraglutide)[](https://app.peptrackerpro.com/?add=maridebart-cafraglutide) ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. [Weight Management](/benefits/weight-management)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)[muscle-preservation](/benefits/muscle-preservation) [View Details](/peptides/met-233i) [\+ Compare](/compare?select=met-233i)[](https://app.peptrackerpro.com/?add=met-233i) ### Pep19 Low Evidence An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss. [Fat Loss](/benefits/fat-loss)[Metabolism](/benefits/metabolism)[Sleep](/benefits/sleep)[cardiometabolic](/benefits/cardiometabolic) [View Details](/peptides/pep19) [\+ Compare](/compare?select=pep19)[](https://app.peptrackerpro.com/?add=pep19) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss) [View Details](/peptides/survodutide) [\+ Compare](/compare?select=survodutide)[](https://app.peptrackerpro.com/?add=survodutide) ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+1 more [View Details](/peptides/tirzepatide) [\+ Compare](/compare?select=tirzepatide)[](https://app.peptrackerpro.com/?add=tirzepatide) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.